What happened?
Shares of biotechnology company Moderna (NASDAQ: MRNA) jumped 6.4% in the afternoon session after the company reported third-quarter 2026 financial results, with revenue rising 29% to $1.3 billion, and raised its full-year revenue growth forecast.
According to a company press release, Moderna reported third-quarter revenue of $1.3 billion, up from $1.0 billion in the third quarter of 2025. The company also posted GAAP net income of $0.2 billion and GAAP diluted earnings per share of 38 cents. It increased its projected full-year 2026 revenue growth to a range of 15% to 25%, above its prior expectation of up to 10% growth.
Is now the time to buy Moderna? Access our full analysis report here, it’s free.
What is the market telling us
Moderna’s shares are extremely volatile and have had 66 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 2 days ago when the stock gained 8.5% on the news that election results confirmed that Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty around drug pricing policy.
As reported by CNBC, Wall Street analysts project that the biopharmaceutical sector's recovery will strengthen in the wake of the congressional election outcome. Investors had feared potential disruptions to healthcare policies, but analysts noted that drug pricing legislation is unlikely to dominate the new legislative agenda. Prior statutory frameworks already established expanding annual Medicare price negotiations, meaning existing government policies will remain intact without unexpected new restrictions.
Furthermore, broader equity markets and index futures rebounded as investors interpreted the shifting balance of power in Washington as a stabilizing dynamic. The presence of congressional checks and balances is widely viewed by market strategists as a moderating force on executive policy decisions, creating a predictable regulatory climate that supports ongoing investments across pharmaceutical and biotechnology developers.
Moderna is up 739% since the beginning of the year, and at $258.80 per share, it has set a new 52-week high. Investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at an investment worth $1,058.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
